- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06173349
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
A Phase I Microtrial With PLZ4-Coated Paclitaxel-Loaded Micelles (PPM) in Patients With Recurrent or Refractory Non-Myoinvasive Bladder Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. Evaluate the safety and tolerability of PPM administered through intravesical instillation.
SECONDARY OBJECTIVES:
I. Evaluate tumor response at 6 weeks after completion of PPM intravesical therapy.
II. Assess event-free survival rate at 12 months.
OUTLINE:
Patients receive PPM intravesically over 1 hour once a week (QW) for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET), and cystoscopy with biopsy at screening and follow up and undergo collection of blood samples throughout the trial.
After completion of study treatment, patients are followed up at 3 weeks, 6 weeks, and then every 3 months per standard of care for 2 years.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- Recruiting
- University of California Davis Comprehensive Cancer Center
-
Principal Investigator:
- Mamta Parikh, MD
-
Contact:
- Mamta Parikh, MD
- Phone Number: 916-734-3772
- Email: mbparikh@ucdavis.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed non muscle invasive bladder cancer (NMIBC), defined as noninvasive papillary carcinoma (Ta), carcinoma in situ (CIS) or carcinoma invading the subepithelial connective tissue (T1), determined via transurethral resection of bladder tumor (TURBT) within 3 months of enrollment
Participant must have Bacillus Calmette Guerin (BCG)-unresponsive NMIBC or intolerance of treatment with BCG. BCG-unresponsive disease is defined as being at least one of the following:
- Persistent or recurrent CIS alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the subepithelial connective tissue) disease within 12 months of completion of adequate BCG therapy
- Recurrent high-grade Ta/T1 disease within 12 months of completion of adequate BCG therapy
T1 high-grade disease at the first evaluation following an induction BCG course. In this context, adequate BCG therapy is defined as at least one of the following:
- At least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy
- At least five of six doses of an initial induction course plus at least two of six doses of a second induction course
- Refuse or intolerant of a radical cystectomy recommended by the treating urologist as the standard next therapy per American Urological Association (AUA) guideline
- Age ≥ 18 years at time of consent
- Performance status: Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Patient with life expectancy greater than 24 months
- No concurrent radiotherapy, chemotherapy, or other immunotherapy for bladder cancer. No BCG or other intravesical treatment within 4 weeks
- No scheduled radiotherapy, chemotherapy, other immunotherapy, or surgery before the scheduled response evaluation
- Recovery from prior treatment side effects that might interfere with the study treatment, in the judgment of the investigator
- Absolute neutrophil count (absolute granulocyte count [AGC]/absolute neutrophil count [ANC]) ≥ 1,500/µL
- Platelets ≥ 100,000/µL (Patients may be transfused to meet this requirement)
- Hemoglobin ≥ 8 g/dL (Patients may be transfused to meet this requirement)
- Calculated glomerular filtration rate (GFR) ≥ 30 mL/min
- Total bilirubin ≤ 2.0 × institutional upper limit of normal (ULN) (< 3 × ULN for patients with Gilbert's syndrome)
- Aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) ≤ 3.0 × institutional ULN
- Adequate pulmonary function by clinical assessment with no clinical signs of severe pulmonary dysfunction
- Participants of childbearing potential must agree to using adequate contraception (e.g., hormonal or barrier method of birth control; abstinence, an intrauterine device) for the duration of study participation (including dosing interruptions) and up to 3 months after last study treatment; or be surgically sterilized (e.g., hysterectomy, tubal ligation, or vasectomy)
- Ability to understand and willingness to sign an informed consent form
- Ability and willingness to adhere to the study visit schedule and other protocol requirements
Exclusion Criteria:
- Existence of cancer at the upper urinary tract
- Concurrent use of other investigational agents
- Evidence of regional and/or distant metastasis
- NYHA (New York Heart Association) class III or IV heart failure, uncontrollable supraventricular arrhythmias, any history of a ventricular arrhythmia, or other clinical signs of severe cardiac dysfunction
- Symptomatic congestive heart failure (CHF), severe/unstable angina pectoris, or myocardial infarction within 6 months prior to study entry
- Patient has an intractable bleeding disorder (e.g., coagulation factors deficiencies, Von Willebrand Disease)
- Patient taking medications that affect coagulation, such as aspirin (though, aspirin 81 mg oral once daily is allowed), Coumadin/Warfarin, heparin, low molecular weight heparin, direct thrombin inhibitors, and direct factor Xa inhibitors. Other nonsteroidal antiinflammatory drugs (NSAIDs) are allowed as long as they are discontinued the day before therapy
- History or evidence of uncontrollable central nervous system (CNS) disease
- Active systemic infection requiring parenteral antibiotic therapy
- Women who are pregnant or breast feeding
Any other malignancy diagnosed within 3 years of trial entry with the exception of the following:
- Basal or squamous cell skin cancers, or
- Noninvasive cancer of the cervix, or
- Any other cancer deemed to be of low-risk for progression or patient morbidity during trial period, such as localized prostate cancer after definitive treatment and prostate-specific antigen (PSA) less than 0.2 ng/mL
- Any condition that would prohibit the understanding or rendering of informed consent
- Any condition that in the opinion of the investigator would interfere with the participant's safety or compliance while on trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PLZ4-coated paclitaxel loaded micelles (PPM)
Patients receive PPM intravesically over 1 hour QW for 6 weeks in the absence of disease progression or unacceptable toxicity.
Patients also undergo CT, MRI, or PET, and cystoscopy with biopsy at screening and follow up and undergo collection of blood samples throughout the trial.
|
Given PLZ4-coated paclitaxel loaded micelles intravesically
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment related adverse events
Time Frame: From first dose of study medication through 12 months after the last dose
|
Number of participants experiencing treatment-related AEs, classified by severity and graded according to the NCI CTCAE v5.0
|
From first dose of study medication through 12 months after the last dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor response
Time Frame: At 6 weeks after the last dose of study medication
|
Assessment of response will be based on visual evaluation (cystoscopy), biopsy of remaining lesion (where technically feasible) and urine cytology.
|
At 6 weeks after the last dose of study medication
|
Event-free survival
Time Frame: From first dose of study medication to first documentation of objective tumor progression, disease recurrence, bladder resection or irradiation, other anti-bladder cancer therapy, or to death due to disease progression, assessed at 12 months
|
From first dose of study medication to first documentation of objective tumor progression, disease recurrence, bladder resection or irradiation, other anti-bladder cancer therapy, or to death due to disease progression, assessed at 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mamta Parikh, University of California, Davis
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Urinary Bladder Diseases
- Disease Attributes
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Recurrence
- Urinary Bladder Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Albumin-Bound Paclitaxel
Other Study ID Numbers
- UCDCC#309 (Other Identifier: University of California Davis Comprehensive Cancer Center)
- P30CA093373 (U.S. NIH Grant/Contract)
- NCI-2023-10047 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage 0a Bladder Cancer AJCC v8
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedErlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial CancerRecurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent Ureter Urothelial Carcinoma | Recurrent Urethral Urothelial Carcinoma | Stage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage 0a Bladder Cancer... and other conditionsUnited States
-
Mayo ClinicRecruitingStage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage II Bladder Cancer AJCC v8United States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedStage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8United States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedStage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer AJCC v8 | Stage III Renal Pelvis and Ureter Cancer AJCC v8 | Stage IV Renal Pelvis and Ureter Cancer AJCC v8 | Stage 0a Renal Pelvis and Ureter Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedStage III Bladder Cancer AJCC v8 | Stage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage IIIB Bladder Cancer AJCC v8 | Urethral Urothelial Carcinoma | Stage II Bladder Cancer AJCC v8 | Stage II Renal Pelvis... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedStage III Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage IIIB Bladder Cancer AJCC v8 | Stage II Bladder Cancer AJCC v8United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Prostate Cancer AJCC v8 | Hepatobiliary Neoplasm | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Malignant Neoplasm and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingBladder Urothelial Carcinoma In Situ | Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Invasive Bladder Mixed CarcinomaUnited States, Guam, Puerto Rico
-
University of California, DavisNational Cancer Institute (NCI); IO BiotechRecruitingStage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | High Risk Non-Muscle Invasive Bladder Urothelial CarcinomaUnited States
-
M.D. Anderson Cancer CenterRecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma AJCC v8 and other conditionsUnited States
Clinical Trials on PLZ4-coated paclitaxel loaded micelles (PPM)
-
VA Office of Research and DevelopmentUniversity of California, DavisRecruiting